Article Image

Whether in Person or Remote, RSNA 2021 Was a Smooth Success

Op-Med is a collection of original articles contributed by Doximity members.

It is that time of the year again and, as always, full of excitement as we look forward to what awaits us at the annual RSNA meeting. Some of us have packed our bags and traveled to Chicago, some are joining remotely via the virtual option, and others are enjoying the best of best worlds with the hybrid experience. 

When I reviewed this year’s schedule, I was pleased to see the broad scope of lectures with more than 400 livestreamed and on-demand courses from all Radiology subspecialties. It was inspiring to see RSNA’s focus on professionalism, diversity, equity, and inclusion. 

The availability of virtual meetings has proved highly valuable. The online option not only helps us to attend sessions during RSNA but also allows us to catch up later — through April 30, 2022 — with the sessions and lectures we were unable to attend during the conference.

As a nuclear radiologist and head of nuclear therapies at Mayo Clinic in Rochester, I am always excited to see sessions on molecular imaging and therapies. I am one of the speakers at the session on Molecular Imaging and Therapies, focusing on prostate cancer imaging and treatment, including Lu-PSMA therapy. The results of the late-stage VISION trial, assessing the role of Lu-PSMA therapy in metastatic castration-resistant prostate cancer, have been recently published. Lu-PSMA-617 is under FDA review. Mayo Clinic in Rochester has proudly been one of the sites for the VISION trial with the highest number of patient accruals. I have been the principal investigator of this study at Mayo Clinic in Rochester and am looking forward to presenting on Lu-PSMA therapy at RSNA. I also am excited for the many opportunities to attend sessions on PET and MRI, molecular imaging (with a focus on Lu-DOTATATE therapy, which has been FDA approved for Somatostatin-receptor-positive metastatic gastroenteropancreatic neuroendocrine tumors, including foregut, midgut, and hindgut neuroendocrine tumors in adults), oncologic imaging, and professionalism.

I will also allow myself ample time for the many educational exhibits and courses and opportunities to meet with vendors. I find industry presentations at RSNA helpful in learning more about new technologies.

RSNA has been a great environment to meet with experts and connect with colleagues. I also enjoy staying current with news and events by following RSNA on Twitter and in the Daily Bulletin to catch highlights of the meeting.

Importantly, the 107th Scientific Assembly and Annual Meeting is dedicated to the memory of Sanjiv Gambhir, M.D., Ph.D., one of the pioneering physician-scientists in my field of nuclear radiology, and Lawrence Bassett, M.D., one of the leaders and pioneers of breast imaging.

Of course, one highlight of RSNA is also its location. Chicago always proves to be a great destination for restaurants, culture, and history. If you like shopping, the Magnificent Mile will not only offer multiple shops, but also my favorite — lights on trees!

Dr. Kendi is employed by the Mayo Clinic and is the principal investigator of the VISION trial at Mayo Clinic Rochester site.

Image by eamesBot / Shutterstock

All opinions published on Op-Med are the author’s and do not reflect the official position of Doximity or its editors. Op-Med is a safe space for free expression and diverse perspectives. For more information, or to submit your own opinion, please see our submission guidelines or email

More from Op-Med